PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma

Lung Cancer

Volumn 89, Issue 2, 2015, Pages 181-188

  Cooper, Wendy A ^a,b,c   Tran, Thang ^a   Vilain, Ricardo E ^a,b,d   Madore, Jason ^d   Selinger, Christina I ^a   Kohonen Corish, Maija ^c,e,f   Yip, PoYee ^a,b,e,g   Yu, Bing ^a,b   O'Toole, Sandra A ^a,b,e   McCaughan, Brian C ^h   Yearley, Jennifer H ⁱ   Horvath, Lisa G ^a,b   Kao, Steven ^a,b   Boyer, Michael ^a,b   Scolyer, Richard A ^a,b,d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g CAMPBELLTOWN HOSPITAL   (Australia)

^h Suite 304   (Australia)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biomarker; Immunohistochemistry; Immunotherapy; Lung cancer; NSCLC; Programmed death ligand 1

Indexed keywords

K RAS PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; VASCULOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INVESTIGATIVE PROCEDURES; LARGE CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR VOLUME; CANCER GRADING; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84937629074     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.05.007     Document Type: Article

References (47)

1. Hanahan D., Weinberg R. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Stewart T.J., Abrams S.I. How tumours escape mass destruction. Oncogene 2008, 27:5894-5903.
3. Dunn G., Bruce A., Ikeda H., Old L., Schreiber R. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
4. Blank C., Gajewski T., Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005, 54:307-314.
5. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. J Exp Med 2000, 192:1027-1034.
6. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
7. Afreen S., Dermime S. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. Hematol Oncol Stem Cell Ther 2014, 7:1-17.
8. Azuma K., Ota K., Kawahara A., Hattori S., Iwama E., Harada T., et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancer. Ann Oncol 2014, 25:1935-1940.
9. Boland J.M., Kwon E.D., Harrington S.M., Wampfler J.A., Tang H., Yang P., et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013, 14:157-163.
10. Chen Y., Mu C., Huang J. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 2012, 98:751-755.
11. Mu C., Huang J., Chen Y., Chen C., Zhang X. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011, 28:682-688.
12. Yang C., Lin M., Chang Y., Wu C., Yang P. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014, 50:1361-1369.
13. Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007, 13:2151-2157.
14. Droeser R.A., Hirt C., Viehl C.T., Frey D.M., Nebiker C., Huber X., et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013, 49:2233-2242.
15. Wu C., Zhu Y., Jiang J., Zhao J., Zhang X., Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006, 108:19-24.
16. Schalper K.A., Velcheti V., Carvajal D., Wimberly H., Brown J., Pusztai L., et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014, 20:2773-2782.
17. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci 2007, 104:3360-3365.
18. Karim R., Jordanova E.S., Piersma S.J., Kenter G.G., Chen L., Boer J.M., et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009, 15:6341-6347.
19. Thompson R., Kuntz S., Leibovich B., Dong H., Lohse C., Webster W., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006, 66:3381-3385.
20. Nakanishi J., Wada Y., Matsumoto K., Azuma M., Kikuchi K., Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007, 56:1173-1182.
21. Hino R., Kabashima K., Kato Y., Yagi H., Nakamura M., Honjo T., et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010, 116:1757-1766.
22. Madore J., Vilain R., Menzies A., Kakavand H., Willmott J., Hyman J., et al. PD-L1 expression in melanoma has prognostic significance but shows marked heterogeneity within and between patients- implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015, 28:245-253.
23. Taube J., Anders R., Young G., Xu H., Sharma R., McMiller T., et al. Colocalization of Inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4:127-137.
24. Iwa Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002, 99:12293-12297.
25. Strome S.E., Dong H., Tamura H., Voss S.G., Flies D.B., Tamada K., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003, 63:6501-6505.
26. Zhang Y., Huang S., Gong D., Qin Y., Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010, 7:389-395.
27. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
28. Brahmer J.R., Tykodi S.S., Chow L.Q.M., Hwu W.-J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
29. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
30. World Health Organisation Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Muller-Hermelink, C.C. Harris (Eds.).
31. American Joint Committee on Cancer AJCC Cancer Staging Manual 2010, Springer, New York. 7th ed.
32. Cooper W., Kohonen-Corish M., McCaughan B., Kennedy C., Sutherland R., Lee C. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology 2009, 55:28-36.
33. Cooper W., Kohonen-Corish M., Zhuang L., McCaughan B., Kennedy C., Screaton G., et al. Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions. Cancer 2008, 113:135-142.
34. Selinger C., Cooper W., Al-Sohaily S., Mladenova D., Pangon L., Kennedy C., et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol 2011, 6:1-11.
35. Yip P., Yu B., Cooper W., Selinger C., Ng C., Kennedy C., et al. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. J Thorac Oncol 2013, 8:408-414.
36. Selinger C.I., Rogers T.M., Russell P.A., O'Toole S.A., Yip P.Y., Wright G.M., et al. Testing for ALK rearrangement in lung adenocarcinoma - a multicenter comparison of immunohistochemisty and fluorescent in situ hybridization. Mod Pathol 2013, 26:1545-1633.
37. Konishi J., Yamazaki K., Azuma M., Kinoshita I., Dosaka-Akita H., Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004, 10:5094-5100.
38. Velcheti V., Schalper K., Carvaja D., Anagnostou V., Syrigos K., Sznol M., et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig 2014, 94:107-116.
39. Harbison C., Kurland J., Cogswell J., Hu X., Han X., Horak C., et al. Characterization of PD-L1 expression and assessment of association with tumor histology and gene expression status in pretreatment non-small cell lung cancer (NSCLC) tumor specimens. J Thorac Oncol 2013, 8:s1092.
40. Sun J., Zhou W., Choi Y., Choi S., Kim S., Wang Z., et al. PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea. J Clin Oncol 2014, 32(5s). [suppl; abstr 8066].
41. Aerts J., Lievense L., Hoogsteden H., Hegmans J. Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res 2014, 3:34-45.
42. Akbay E.A., Koyama S., Carretero J., Altabef A., Tchaicha J.H., Christensen C.L., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013, 3:1355-1363.
43. Ishii H., Azuma K., Kawahara A., Yamada K., Imamura Y., Tokito T., et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol 2014, [E-pub ahead of print].
44. Zheng X., Bu Z., Liu X., Zhang L., Li Z., Wu A., et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res 2014, 10:4-11.
45. Sorenson S., Zhou W., Dolled-Filhart M., Georgsen J., Wang Z., Emancipator K., et al. PD-L1 expression and survival among advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy. Ann Oncol 2014, 25(Suppl. 4):iv426-iv470.
46. Ohigashi Y., Sho M., Yamada Y., Tsurui Y., Hamada K., Ikeda N., et al. Clinical significance of programmed death ligand-1 and programmed death ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005, 11:2947-2953.
47. Gao Q., Wang X.-Y., Qiu S.-J., Yamato I., Sho M., Nakajima Y., et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009, 15:971-979.